No Data
Yifan Pharmaceutical Co., Ltd.'s (SZSE:002019) Prospects Need A Boost To Lift Shares
Yifan Pharmaceutical Secures Registration Approval for Neostigmine Methylsulfate Injection
Yifan Pharmaceutical (002019.SZ): The methanesulfonate neostigmine injection has obtained the pharmaceutical registration certificate.
On November 21, Gelonhui reported that Yifan Pharmaceutical (002019.SZ) announced that its wholly-owned subsidiary, Hefei Yifan Biopharmaceutical Co., Ltd., received the "Drug Registration Certificate" issued by the National Medical Products Administration for the approval of the injection of Neostigmine Methylsulfate in 2024. Neostigmine Methylsulfate injection is an anticholinesterase drug. It is used to antagonize the residual muscle relaxation of non-depolarizing muscle relaxants at the end of surgery and is used for Myasthenia Gravis, functional intestinal bloating after surgery, and urinary retention.
Yifan Pharmaceutical (002019.SZ): Ginkgo Leaf Pill does not involve national talks.
On November 12, Geruihui reported that yifan pharmaceutical (002019.SZ) stated on the investor interaction platform that the national negotiation product this time is dinitrate oral suspension, and ginkgo leaf pill does not involve national negotiation.
Yifan Pharmaceutical (002019.SZ): Currently no shipments to the USA market.
Gelonghui, November 7th | yifan pharmaceutical (002019.SZ) stated on the investor interaction platform that there are currently no shipments to the usa market.
Yifan Pharmaceutical Co., Ltd. (SZSE:002019) Surges 6.4%; Individual Investors Who Own 50% Shares Profited Along With Insiders
Yifan Pharmaceutical Co., Ltd.'s (SZSE:002019) Share Price Not Quite Adding Up
No Data
